IL6 and rheumatoid arthritis: Second, we cannot rule out the possibility that use of a wide range of antirheumatic drugs-including methotrexate, oral glucocorticoids, anti-TNF-α therapy and anti-IL-6 therapy that potently suppress specific inflammation, might be responsible for the differences in gene expression profiles in OA and RA patients’ MCs.